Heteroresistance to colistin in wild-type Klebsiella pneumoniae isolates from clinical origin

Microbiol Spectr. 2023 Dec 12;11(6):e0223823. doi: 10.1128/spectrum.02238-23. Epub 2023 Nov 14.

Abstract

Colistin is one of the last remaining therapeutic options for dealing with Enterobacteriaceae. Unfortunately, heteroresistance to colistin is also rapidly increasing. We described the prevalence of colistin heteroresistance in a variety of wild-type strains of Klebsiella pneumoniae and the evolution of these strains with colistin heteroresistance to a resistant phenotype after colistin exposure and withdrawal. Resistant mutants were characterized at the molecular level, and numerous mutations in genes related to lipopolysaccharide formation were observed. In colistin-treated patients, the evolution of K. pneumoniae heteroresistance to resistance phenotype could lead to higher rates of therapeutic failure.

Keywords: Klebsiella pneumoniae; colistin; heteroresistance; mgrB.

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Proteins / genetics
  • Colistin* / pharmacology
  • Drug Resistance, Bacterial / genetics
  • Humans
  • Klebsiella Infections* / drug therapy
  • Klebsiella Infections* / epidemiology
  • Klebsiella pneumoniae
  • Microbial Sensitivity Tests

Substances

  • Colistin
  • Anti-Bacterial Agents
  • Bacterial Proteins